iBio (IBIO) 10-K 15 Sep 17 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2017	Sep. 15, 2017	Dec. 30, 2016
Document Information [Line Items]
Entity Registrant Name	iBio, Inc.
Entity Central Index Key	1,420,720
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 21,262,787
Trading Symbol	IBIO
Entity Common Stock, Shares Outstanding		92,818,510

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Current assets:
Cash	$ 8,088	$ 23,014
Accounts receivable - trade	175	484
Accounts receivable - unbilled	0	122
Work in process	26	22
Prepaid expenses and other current assets	283	264
Total Current Assets	8,572	23,906
Fixed assets, net of accumulated depreciation	25,589	25,574
Intangible assets, net of accumulated amortization	1,823	2,092
Security deposit	26	28
Total Assets	36,010	51,600
Current liabilities:
Accounts payable (related party of $87 and $200 as of June 30, 2017 and 2016, respectively)	749	1,177
Accrued expenses (related party of $650 and $623 as of June 30, 2017 and 2016, respectively)	924	920
Capital lease obligation - current portion	183	170
Deferred revenue	157	24
Total Current Liabilities	2,013	2,291
Capital lease obligation - net of current portion	25,082	25,265
Total Liabilities	27,095	27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:
Preferred stock - no par value; 1,000,000 shares authorized; 1 and 0 shares issued and outstanding as of June 30, 2017 and 2016, respectively	0	0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,118,510 and 89,109,410 shares issued and outstanding as of June 30, 2017 and 2016, respectively	89	89
Additional paid-in capital	80,977	67,468
Accumulated other comprehensive loss	(29)	(29)
Accumulated deficit	(72,123)	(57,591)
Total iBio, Inc. Stockholders’ Equity	8,914	9,937
Noncontrolling interest	1	14,107
Total Equity	8,915	24,044
Total Liabilities and Equity	$ 36,010	$ 51,600

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Accounts payable, related parties	$ 87	$ 200
Accrued expenses, related parties	$ 650	$ 623
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	1	0
Preferred stock, shares outstanding (in shares)	1	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares issued (in shares)	89,118,510	89,109,410
Common stock, shares outstanding (in shares)	89,118,510	89,109,410

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Revenues	$ 394	$ 948
Operating expenses:
Research and development (related party of $957 and $1,036), net of grant income of $131 and $65	4,117	3,156
General and administrative (related party of $775 and $565)	10,551	7,685
Total operating expenses	14,668	10,841
Operating loss	(14,274)	(9,893)
Other income (expense):
Interest expense (related party of $1,928 and $807)	(1,929)	(807)
Interest income	39	22
Royalty income	25	21
Total other income (expense)	(1,865)	(764)
Consolidated net loss	(16,139)	(10,657)
Net loss attributable to noncontrolling interest	1,607	893
Net loss attributable to iBio, Inc.	(14,532)	(9,764)
Preferred stock dividends	(90)	0
Net loss available to iBio, Inc.	(14,622)	(9,764)
Comprehensive loss:
Consolidated net loss	(16,139)	(10,657)
Other comprehensive loss - foreign currency translation adjustments	0	(4)
Comprehensive loss	$ (16,139)	$ (10,661)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted	$ (0.16)	$ (0.12)
Weighted-average common shares outstanding - basic and diluted	89,112	80,973

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating expenses research and development, related party	$ 957	$ 1,036
Operating expenses general and administrative, related party	775	565
Interest Expense, Related Party	1,928	807
Revenue from Grants	$ 131	$ 65

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Accumulated Other Comprehensive Loss [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Balance at Jun. 30, 2015	$ 11,231	$ (25)	$ 0	$ 77	$ 59,006	$ (47,827)	$ 0
Balance (in shares) at Jun. 30, 2015			0	77,206
Capital contribution - noncontrolling interest	15,000	0	$ 0	$ 0	0	0	15,000
Sale of common stock	6,220	0	$ 0	$ 10	6,210	0	0
Sale of common stock (in shares)			0	10,000
Exercises of warrants (in shares)			0	1,904
Exercises of warrants	1,009	0	$ 0	$ 2	1,007	0	0
Share-based compensation	1,245	0	0	0	1,245	0	0
Foreign currency translation adjustment	(4)	(4)	0	0	0	0	0
Net loss	(10,657)	0	0	0	0	(9,764)	(893)
Balance at Jun. 30, 2016	24,044	(29)	$ 0	$ 89	67,468	(57,591)	14,107
Balance (in shares) at Jun. 30, 2016			0	89,110
Issuance of preferred stock for acquisition of additional interest in subsidiary	0	0	$ 0	$ 0	12,499	0	(12,499)
Share-based compensation	1,010	0	0	0	1,010	0	0
Other adjustment	0	0	$ 0	$ 0	0	0	0
Other adjustment (in shares)			0	9
Foreign currency translation adjustment	0	0	$ 0	$ 0	0	0	0
Net loss	(16,139)	0	0	0	0	(14,532)	(1,607)
Balance at Jun. 30, 2017	$ 8,915	$ (29)	$ 0	$ 89	$ 80,977	$ (72,123)	$ 1
Balance (in shares) at Jun. 30, 2017			0	89,119

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (16,139)	$ (10,657)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	1,010	1,245
Amortization of intangible assets	350	363
Depreciation	1,326	577
Loss on abandonment of intangible assets	0	33
Changes in operating assets and liabilities
Accounts receivable - trade	309	(39)
Accounts receivable - unbilled	122	(122)
Work in process	(4)	(22)
Prepaid expenses and other current assets	(19)	(82)
Security deposit	2	(28)
Accounts payable	(257)	(125)
Accrued expenses	4	761
Deferred revenue	133	24
Net cash used in operating activities	(13,163)	(8,072)
Cash flows from investing activities:
Additions to intangible assets	(270)	0
Purchases of fixed assets	(1,323)	(68)
Net cash used in investing activities	(1,593)	(68)
Cash flows from financing activities:
Proceeds from sale of common stock	0	6,220
Proceeds from exercise of warrants	0	1,009
Capital contribution - noncontrolling interest	0	15,000
Payment of capital lease obligation	(170)	(565)
Net cash (used in) provided by financing activities	(170)	21,664
Effect of exchange rate changes	0	(4)
Net increase (decrease) in cash	(14,926)	13,520
Cash - beginning of year	23,014	9,494
Cash - end of year	8,088	23,014
Schedule of non-cash activities:
Issuance of preferred stock for acquisition of additional interest in subsidiary	12,499	0
Unpaid intangible assets included in accounts payable	7	129
Fixed assets included in accounts payable in FY 2016, paid in FY 2017	(71)	0
Unpaid fixed assets included in accounts payable	87	71
Purchase of fixed assets financed by capital lease	0	26,000
Supplemental cash flow information:
Cash paid during the year for interest	$ 1,930	$ 485

Nature of Business

Nature of Business	12 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Nature of Business iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on using our proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators and third-party customers as well as developing and commercializing our own product candidates. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows: iBioDefense Biologics LLC iBio Peptide Therapeutics LLC iBIO DO BRASIL BIOFARMACÊUTICA LTDA iBio Manufacturing LLC iBio CDMO LLC On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate, pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Company’s iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns 99.99% of iBio CDMO. See Note 11 for a further discussion. iBio CDMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000-square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Eastern Affiliate granted iBio CDMO a 34-year capital lease for the facility as well as certain equipment (see Note 10). Commercial operations commenced in January 2016. iBio CDMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third-party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases and/or other proprietary iBio products; and (3) Commercial technology transfer including facility design, as needed

Basis of Presentation

Basis of Presentation	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. Basis of Presentation Going Concern Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. The Company’s net loss was approximately $ 16.1 10.7 72.1 13.2 The Company has historically financed its activities through the sale of common stock and warrants. Through June 30, 2017, the Company has dedicated most of its financial resources to research and development, including the development and validation of its own technologies and the development of a proprietary therapeutic product against fibrosis based upon those technologies, advancing its intellectual property, the build-out and recommissioning of its CDMO facility, and general and administrative activities. As of June 30, 2017, the Company has not completed development of or commercialized any vaccine or therapeutic product candidates. As such, the Company expects to continue to incur significant expenses and operating losses for at least the next year. The Company anticipates that its expenses and losses will increase substantially if the Company: · initiates clinical trials of its product candidates; · continues the research and development of our product candidates; · seeks · adds operational, financial and management information systems and personnel, including personnel to support our product development and manufacturing efforts. To become and remain profitable, the Company must succeed in commercializing its technologies or the Company, alone or with its licensees, must succeed in developing and eventually commercializing products that generate significant revenue. In addition, profitability will depend on continuing to attract and maintain customers for the development, manufacturing and technology transfer services offered by the Company’s subsidiary iBio CDMO. On July 24, 2017, the Company entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), an Illinois limited liability company, pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $ 16,000,000 1,200,000 2,500,000 1,000,000 The extent to which the Company utilizes the purchase agreement with Lincoln Park as a source of funding will depend on a number of factors, including the prevailing market price of the Company’s common stock, the volume of trading in the Company’s common stock and the extent to which the Company is able to secure funds from other sources. The number of shares that the Company may sell to Lincoln Park under the purchase agreement on any given day and during the term of the agreement is limited. Additionally, the Company and Lincoln Park may not effect any sales of shares of our common stock under the purchase agreement during the continuance of an event of default under the purchase agreement. On November 20, 2014, the Company filed with the Securities and Exchange Commission a Registration Statement on Form S-3 under the Securities Act, which was declared effective by the Securities and Exchange Commission on December 2, 2014. This registration statement allows the Company, from time to time, to offer and sell shares of common stock, shares of preferred stock, debt securities, units comprised of shares of common stock, preferred stock, debt securities and warrants in any combination, and warrants to purchase common stock, preferred stock, debt securities and/or units, up to a maximum aggregate amount of $ 100 On January 13, 2016, the Company entered into a contract manufacturing joint venture with the Eastern Affiliate. The Eastern Affiliate contributed $15 million in cash for a 30% interest in the Company’s subsidiary iBio CDMO LLC (“iBio CDMO”). The Company retained a 70% interest in iBio CDMO and contributed a royalty bearing license which grants iBio CDMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Company’s iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns 99.99% of iBio CDMO. On January 13, 2016, the Company also entered into share purchase agreements with Eastern pursuant to which Eastern agreed to purchase 10 0.622 3,500,000 6,500,000 1,784,000 0.53 As of the date of the filing of this report, iBio CDMO received $ 15 7.2 10 Prior to the issuance of the shares of common stock pursuant to the purchase agreements with Eastern, Eastern beneficially owned approximately 30% of the Company’s common stock, as reported in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015, filed with the SEC on October 13, 2015, calculated in accordance with the SEC’s beneficial ownership rules. As of the closing of the purchase agreements with Eastern and the simultaneous exercise by Eastern of its warrants to purchase iBio common stock, Eastern beneficially owned approximately 38% of the Company’s outstanding shares of common stock. As of the filing date of this report, Eastern owns approximately 36.4% of the Company’s outstanding common stock. See Note 11 in the consolidated financial statements On May 15, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) pursuant to which the Company had the option to require Aspire Capital to purchase up to $ 15 No shares were sold under the 2015 Facility. See Note 11 for a further description of the agreement. The agreement with Aspire was terminated on July 21, 2017. The history of significant losses, the negative cash flow from operations, the limited cash resources currently on hand and the dependence by the Company on its ability – about which there can be no certainty – to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company’s ability to continue as a going concern. These financial statements were prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Lincoln Park pursuant to the common stock purchase agreement entered into on July 24, 2017, and through proceeds realized in connection with license and collaboration arrangements and the operation of our subsidiary, iBio CDMO. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on management's estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June 30, 2017 and 2016, the Company determined that an allowance for doubtful accounts was not needed. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In 2017 and 2016, grant income amounted to approximately $ 131,000 65,000 Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. Work in process totaled approximately $ 26,000 22,000 The Company accounts for research and development costs in accordance with the FASB ASC 730-10, “ Research and Development Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years. Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 10). The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23 The Company does not use derivative instruments in its ordinary course of business. In connection with the issuances of debt and/or equity instruments, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities rather than as equity. In addition, the debt and/or equity instrument may contain embedded derivative instruments, such as conversion options or anti-dilution features, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company accounts for derivative liability instruments under the provisions of FASB ASC 815, “ Derivatives and Hedging There are no options or warrants of the Company presently outstanding that require accounting as a derivative liability. The Company accounts for foreign currency translation pursuant to FASB ASC 830, “ Foreign Currency Matters. The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates. The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at the date of grant or modification, and the vesting schedule. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June 30, 2017 and 2016. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2017 and 2016. Concentration of Credit Risk Cash The Company maintains principally all cash balances in one financial institution which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2017 and 2016, amounts in excess of insured limits were approximately $ 7,623,000 22,502,000

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Jun. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	4. New Accounting Pronouncements In May 2014, FASB Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period Effective June 30, 2017, the Company adopted ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Effective January 1, 2016, the Company adopted ASU 2015-01, “ Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” On January 1, 2017, the Company adopted ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers In May 2016, the FASB issued ASU 2016-12, " Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In October 2016, the FASB issued ASU 2016-16, “ Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued ASU 2016-17, “ Consolidation (Topic 810): Interests Held Through Related Parties That Are Under Common Control In January 2017, the FASB issued ASU 2017-01, “ Business Combinations (Topic 805): Clarifying the Definition of a Business In May 2017, the FASB issued ASU 2017-09, “ Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting ”

Financial Instruments and Fair

Financial Instruments and Fair Value Measurement	12 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	5. Financial Instruments and Fair Value Measurement The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company's consolidated balance sheets approximated their fair values as of June 30, 2017 and 2016 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value at June 30, 2017 as the interest rate used to discount the lease payments approximated market.

Fixed Assets

Fixed Assets	12 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. Fixed Assets iBio CDMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Eastern Affiliate under the Sublease. See Note 10 for more details of the terms of the Sublease. June 30, June 30, Facility under capital lease $ 20,000 $ 20,000 Equipment under capital lease 6,000 6,000 Facility improvements 332 42 Medical equipment 905 - Office equipment and software 256 137 27,493 26,179 Accumulated depreciation – assets under capital lease (1,805) (571) Accumulated depreciation – other (99) (34) (1,904) (605) Net fixed assets $ 25,589 $ 25,574 Depreciation expense was approximately $ 1,326,000 577,000 1,235,000 571,000

Intangible Assets

Intangible Assets	12 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	7. Intangible Assets The Company has two categories of intangible assets – patents and other intellectual property. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). The Company designates such technology further developed by and acquired from Fraunhofer as iBioLaunch™ technology or as iBioModulator™ technology. The value on the Company’s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company’s patent portfolio. The intellectual property also includes certain trademarks. In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the “Licensed Technology”). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (“IND”) – initially became due on December 1, 2015, and on August 11, 2016, the agreement was amended and subsequent six-month extensions have been automatically granted extending the due date until December 31, 2017. The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges during 2017 and 2016. June 30, June 30, Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,346 2,265 5,446 5,365 Intellectual property – accumulated amortization (2,088) (1,932) Patents – accumulated amortization (1,535) (1,341) (3,623) (3,273) Net intangible assets $ 1,823 $ 2,092 Amortization expense, included in general and administrative expenses, was approximately $ 350,000 363,000 0 6.3 7.5 For the Year Ending 2018 $ 335 2019 305 2020 273 2021 252 2022 238 Thereafter 420 Total $ 1,823

Significant Vendors

Significant Vendors	12 Months Ended
	Jun. 30, 2017
Significant Vendor [Abstract]
Significant Vendor Disclosures [Text Block]	8. Significant Vendors Novici Biotech, LLC In January 2012, the Company entered into an agreement with Novici Biotech, LLC (“Novici”) in which iBio’s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $ 87,000 200,000 957,000 1,036,000 Fraunhofer Previously, Fraunhofer had been the Company’s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below) but expenses have decreased due to changes and a decrease in technology services performed pursuant to the agreement with Fiocruz. The accounts payable balance under this three-party agreement includes amounts due Fraunhofer of approximately $ 75,000 341,000 0 122,000 On January 4, 2011, the Company entered into the Collaboration and License Agreement (the “CLA”) which is a three-party agreement involving the Company, Fraunhofer and Fiocruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provided for the development of a Yellow Fever vaccine to be manufactured and distributed within Latin America and Africa by Fiocruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the “Agreement”). The CLA provides for services to be billed to Fiocruz at Fraunhofer’s cost, so the Company’s revenue is equivalent to expense and there is no profit. On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. In 2017 and 2016, under the Amended Agreement, the Company recognized revenue of $ 137,000 758,000 iBio and Fiocruz are currently evaluating plans for further collaboration without prospective reliance on older Fraunhofer-derived technology and data. In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “2013 Settlement Agreement”). Under the terms of the 2013 Settlement Agreement, various payment obligations, including accrued payment obligations existing at June 30, 2013, were released, terminated or modified. See Note 16 - Commitments and Contingencies for significant modifications. On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer's Executive Director. See Note 16 - Lawsuits for additional information.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accrued Expenses Disclosure [Text Block]	9. Accrued Expenses June 30, June 30, Rent and real estate taxes – related party (see Note 14) $ 330 $ 300 Interest – related party (see Note 14) 320 323 Professional fees 56 15 Salaries and benefits 111 55 Research and development - 122 Facility expenses - 53 Other accrued expenses 107 52 Total accrued expenses $ 924 $ 920

Capital Lease Obligation

Capital Lease Obligation	12 Months Ended
	Jun. 30, 2017
Leases, Capital [Abstract]
Leases of Lessee Disclosure [Text Block]	10. Capital Lease Obligation As discussed above, iBio CDMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Eastern Affiliate under the Sublease. iBio CDMO began operations at the facility on December 22, 2015 pursuant to agreements between iBio CDMO and the Second Eastern Affiliate granting iBio CDMO temporary rights to access the facility. These temporary agreements were superseded by the Sublease Agreement, dated January 13, 2016, between iBio CDMO and the Second Eastern Affiliate. The 34 2,100,000 In addition to the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $107,000 and $27,000 in 2017 and 2016, respectively. Interest expense incurred under the capital lease obligation amounted to $ 1,928,000 807,000 Year Ending: Principal Interest Total 2018 $ 183,110 $ 1,916,890 $ 2,100,000 2019 197,443 1,902,557 2,100,000 2020 212,898 1,887,102 2,100,000 2021 229,562 1,870,438 2,100,000 2022 247,531 1,852,469 2,100,000 Thereafter 24,194,146 34,080,854 58,275,000 Total minimum lease payments 25,264,690 $ 43,510,310 $ 68,775,000 Less: current portion (183,110) Long-term portion of minimum lease obligations $ 25,081,580

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2017
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	11. Stockholders’ Equity Preferred Stock The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 iBio CMO Preferred Tracking Stock On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate and issued one share of a newly created iBio CMO Preferred Tracking Stock, par value $ 0.001 29,990,000 13 99.99 0.01 As described below under “ Eastern – Share Purchase Agreements 38 On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company’s 1 1. The Preferred Tracking Stock accrues dividends at the rate of 2 90,000 2. The holders of Preferred Tracking Stock, voting separately as a class, are entitled to approve by the affirmative vote of a majority of the shares of Preferred Tracking Stock outstanding any amendment, alteration or repeal of any of the provisions of, or any other change to, the Certificate of Incorporation of the Company or the Certificate of Designation that adversely affects the rights, powers or privileges of the Preferred Tracking Stock, any increase in the number of authorized shares of Preferred Tracking Stock, the issuance or sale of any additional shares of Preferred Tracking Stock or any securities convertible into or exercisable or exchangeable for Preferred Tracking Stock, the creation or issuance of any shares of any additional class or series of capital stock unless the same ranks junior to the Preferred Tracking Stock, or the reclassification or alteration of any existing security of the Company that is junior to or pari passu with the Preferred Tracking Stock, if such reclassification or alteration would render such other security senior to the Preferred Tracking Stock. 3. Except as required by applicable law, the holders of Preferred Tracking Stock have no other voting rights. 4. No dividend may be declared or paid or set aside for payment or other distribution declared or made upon the Company’s common stock and no common stock may be redeemed, purchased or otherwise acquired for any consideration by the Company unless all accrued dividends on all outstanding shares of Preferred Tracking Stock are paid in full. At the election of the Company or holders of a majority outstanding shares of Preferred Tracking Stock, each outstanding share of Preferred Tracking Stock may be exchanged for 29,990,000 Common Stock As of June 30, 2017 and 2016, the Company was authorized to issue up to 175 15 Recent issuances of common stock include the following: There was an increase of 9,100 89,109,410 89,118,510 Lincoln Park Purchase Agreement On July 24, 2017, we entered into the Lincoln Park Purchase Agreement pursuant to which Lincoln Park has agreed to purchase from us up to an aggregate of $ 16.0 Under the terms and subject to the conditions of the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to, an additional $ 15.0 As contemplated by the Lincoln Park Purchase Agreement, and so long as the closing price of the Company’s common stock exceeds $ 0.25 100,000 1.0 In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the purchase agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock. There are no trading volume requirements or restrictions under the purchase agreement nor any upper limits on the price per share that Lincoln Park must pay for shares of common stock. The Lincoln Park Purchase Agreement and the registration rights agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the purchase agreement at any time, at no cost or penalty. During any “event of default” under the purchase agreement, all of which are outside of Lincoln Park’s control, Lincoln Park does not have the right to terminate the purchase agreement; however, the Company may not initiate any regular or other purchase of shares by Lincoln Park, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against the Company, the purchase agreement will automatically terminate. Actual sales of shares of common stock to Lincoln Park under the purchase agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. Lincoln Park has no right to require any sales by the Company, but is obligated to make purchases from the Company as it directs in accordance with the purchase agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company’s shares. As a result, on July 24, 2017, 1,200,000 2,500,000 0.40 1,000,000 Other issuances of common stock were as follows: Aspire Capital – 2015 Facility On May 15, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital, pursuant to which the Company had the option to require Aspire Capital to purchase up to an aggregate of $ 15.0 450,000 (the “Commitment Shares”) Pursuant to the 2015 Aspire Purchase Agreement, on any business day after the Commencement Date (as defined below) and over the 36-month term of the 2015 Aspire Purchase Agreement, the Company had the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 200,000 500,000 2,000,000 The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice were determined at the Company’s discretion. The aggregate number of shares that the Company could sell to Aspire Capital under the 2015 Aspire Purchase Agreement could in no case exceed 15,343,406 19.99 450,000 The 2015 Aspire Purchase Agreement contained customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the 2015 Aspire Purchase Agreement could commence only after certain conditions were satisfied (the date on which all requisite conditions have been satisfied being referred to as the “Commencement Date”), which conditions included the delivery to Aspire Capital of a prospectus supplement covering the Commitment Shares and the Purchase Shares, approval for listing on NYSE American of the Purchase Shares and the Commitment Shares, the issuance of the Commitment Shares to Aspire Capital, and the receipt by Aspire Capital of a customary opinion of counsel and other certificates and closing documents. Either party had the option to terminate the 2015 Aspire Purchase Agreement in the event the Commencement Date had not occurred by July 1, 2015. The 2015 Aspire Purchase Agreement was terminable by the Company at any time, at its discretion, without any cost or penalty. The Company’s net proceeds depended on the Purchase Price, the VWAP Purchase Price and the frequency of the Company’s sales of Purchase Shares to Aspire Capital; subject to the maximum $ 15.0 In connection with the 2015 Aspire Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated May 15, 2015. The Registration Rights Agreement provides, among other things, a requirement to register the sale of the Commitment Shares and the Purchase Shares to Aspire Capital pursuant to the Company’s existing shelf registration statement (the “Registration Statement”). The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement. On May 29, 2015, the Company filed a prospectus supplement to the Company’s existing Registration Statement on Form S-3, registering $ 15.0 No shares were sold under the 2015 Facility as of the date of the filing of this report. Aspire Capital – 2014 Facility On August 25, 2014, the Company entered into a common stock purchase agreement with Aspire Capital, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $ 10.0 10.0 In consideration for entering into the purchase agreement, following the approval of the issuance of the shares by NYSE American, Aspire Capital received a commitment fee of $ 300,000 3 681,818 0.44 1,136,354 0.44 500,000 Concurrently with entering into the purchase agreement, the Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements as permissible and necessary to register under the Securities Act of 1933, as amended, the sale of shares of the Company’s common stock under the purchase agreement. After the Securities and Exchange Commission declared effective the registration statement, on any trading day on which the closing sale price of the Company’s common stock exceeded the “Floor Price” of $ 0.44 500,000 In addition, on any date on which the Company submitted a purchase notice to Aspire Capital in an amount equal to 150,000 0.44 30 80 97 The purchase agreement provided that the Company and Aspire Capital could not effect any sales under the purchase agreement on any purchase date where the closing sale price of common stock is less than $ 0.44 0.20 Aspire Capital purchased 8,768,806 10,000,000 10.0 Eastern – Share Purchase Agreements On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 3,500,000 0.622 2,177,000 1,784,000 0.53 945,000 On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 6,500,000 0.622 6,500,000 6,500,000 4,043,000 On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate and issued one share of a newly created iBio CMO Preferred Tracking Stock, par value $0.001 per share (the “Preferred Tracking Stock”), in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by the Eastern Affiliate at an original issue price of $13 million. After giving effect to the transactions contemplated in the Exchange Agreement, the Company owns 99.99% of iBio CDMO and the Eastern Affiliate owns 0.01% of iBio CDMO. Exercises of Warrants In 2016, in addition to the exercise of warrants by Eastern discussed above, t he Company issued 120,000 64,000 No warrants were exercised in 2017 . Warrants The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. Warrants Weighted- Outstanding as of July 1, 2016 6,633,324 $ 1.63 Exercised (1,904,000) 0.53 Expired (4,729,324) 2.08 Outstanding as of June 30, 2016 - $ - Exercised - - Expired - - Outstanding as of June 30, 2017 - $ -

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	12 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	12. Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. Years ended 2017 2016 Basic and diluted numerator: Net loss attributable to iBio, Inc. stockholders $ (14,532) $ (9,764) Preferred stock dividends (90) — Net loss available to iBio, Inc. stockholders $ (14,622) $ (9,764) Basic and diluted denominator: Weighted-average common shares outstanding 89,112 80,973 Per share amount $ (0.16) $ (0.12) In 2017 and 2016, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2017, and 2016, shares issuable which could potentially dilute future earnings included approximately 13.5 12.3

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	13. Share-Based Compensation Year Ended 2017 2016 Research and development $ 26 $ 20 General and administrative 984 1,245 Totals $ 1,010 $ 1,265 Stock Options On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. The original Plan provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 10 Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million. 1.45 Issuances of stock options during 2016 were as follows: On September 4, 2015 and March 1, 2016, the Company granted stock options to members of the Board of Directors, officers and employees to purchase 2.75 1.64 Issuances of stock options during 2017 were as follows: On March 1, 2017, the Company granted stock options to an officer to purchase 150,000 three ten 0.40 In May 2017 through June 2017, the Company granted stock options to members of the Board of Directors, officers and employees to purchase 1,435,000 three ten 0.40 Issuances of stock options for the period from July 1, 2017 to the date of the filing of this report were as follows: On July 1, 2017, the Company granted stock options to an employee to purchase 50,000 three ten 0.40 Stock Weighted- Weighted- Aggregate Outstanding as of July 1, 2015 9,523,334 $ 1.22 6.6 $ 1,848 Granted 2,750,000 $ 1.64 Forfeited/expired - $ - Outstanding as of June 30, 2016 12,273,334 $ 1.31 6.4 $ 993 Granted 1,585,000 $ 0.40 Forfeited/expired (310,000) $ 1.11 Outstanding as of June 30, 2017 13,548,334 $ 1.21 5.9 $ 138 As of June 30, 2017 vested and expected to vest 13,486,342 $ 1.21 5.8 $ 138 Exercisable as of June 30, 2017 9,440,027 $ 1.30 4.7 $ 138 The total fair value of stock options that vested during 2017 and 2016 was approximately $ 1,239,000 800,000 1.1 1.8 The weighted-average grant date fair value of stock options granted during 2017 and 2016 was $ 0.36 0.62 2017 2016 Risk-free interest rate 2.05 2.46 1.83 2.13 Dividend yield 0 0 Volatility 103.10 104.38 109.49 112.17 Expected term (in years) 9 9

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions Novici Biotech, LLC 87,000 200,000 957,000 1,036,000 Agreements with Eastern Capital Limited and its Affiliates. As more fully discussed in Note 11, the Company entered into two share purchase agreements with Eastern and sold 10 0.622 6,220,000 1,784,000 0.53 945,520 Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio’s recently formed subsidiary, iBio CDMO. The Eastern Affiliate contributed $ 15.0 30 70 In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CDMO the Sublease of a Class A life sciences building in Bryan, Texas, on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. Accrued expenses at June 30, 2017 and 2016 due to the Second Eastern Affiliate are $ 650,000 775,000 1,928,000 807,000 A three-year standstill agreement (the “Standstill Agreement”) that took effect upon the issuance of the Eastern Shares pursuant to the 6,500,000 38 On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate and issued one share of the iBio CMO Preferred Tracking Stock, par value $ 0.001 29,990,000 13 Operating Lease with Minority Stockholder Effective January 1, 2015, the Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company. Rent was $ 2,200 2,500 50,000 28,500

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	15. Income Taxes For the Years Ended 2017 2016 United States $ (16,122) $ (10,635) Brazil (17) (22) Total $ (16,139) $ For the Years Ended 2017 2016 Current – Federal, state and foreign $ - $ - Deferred – Federal (5,178) (260) Deferred – State (866) (9) Deferred – Foreign (4) (1) Total (6,048) (270) Change in valuation allowance 6,048 270 Income tax expense $ - $ - The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes. As of June 30, 2017 2016 Deferred tax assets (liabilities): Net operating loss $ 17,827 $ 17,172 Share-based compensation 3,072 726 Research and development tax credits 1,285 1,097 Suspended losses in iBio CDMO 2,762 255 Basis in iBio CDMO 538 145 Intangible assets (267) (219) Vacation accrual and other 24 17 Valuation allowance (25,241) (19,193) Total $ - $ - The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. Federal net operating losses of approximately $ 5.5 U.S. Federal and state net operating losses of approximately $ 50.1 12.9 1.3 119,000 Years Ended 2017 2016 Statutory federal income tax rate 34 % 34 % State (net of federal benefit) 6 % 6 % Research and development tax credit 1 % 1 % Permanent differences (5) % (7) % Reclassification of incentive stock options to non-qualifying 13 % - % Expiration of stock options and warrants - % (31) % Change in valuation allowance (49) % (3) % Effective income tax rate - % - % The Company has not been audited in connection with income taxes. iBio files U.S. Federal and state income tax returns subject to varying statutes of limitations. The 2013 through 2016 tax returns generally remain open to examination by U.S. Federal authorities and the 2013 through 2016 tax returns generally remain open to examination by state tax authorities. In addition, the 2015 through 2017 Brazilian federal tax returns remain open to examination by Brazil’s federal tax authorities.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	16. Commitments and Contingencies Agreements In September 2013, the Company and Fraunhofer entered into an agreement, the Terms of Settlement For TTA Seventh Amendment (the “2013 Settlement Agreement”). Under the terms of the 2013 Settlement Agreement, various payment obligations, including accrued payment obligations existing at June 30, 2013, were released, terminated or modified. The significant modifications are of follows: The Company’s obligation under the TTA, prior to the 2013 Settlement Agreement, to make three $ 1 3 The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $ 200,000 the 2013 Settlement Agreement provided that, 2013 Settlement Agreement provided for royalty payments to Fraunhofer only on technology license revenues that iBio actually would receive, and on revenues from actual sales by iBio of products derived from the technology developed by Fraunhofer under the TTA, until the later of November 2023 or until such time as the aggregate royalty payments totaled at 4 All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and was required to be transferred to iBio, and Fraunhofer was required to make technology transfer, which Fraunhofer refused to perform. In the lawsuit against Fraunhofer, iBio is seeking rescission of these royalty provisions of the 2013 Settlement Agreement. In any event, the 2013 Settlement Agreement does not apply to, and the Company has no financial obligations to Fraunhofer with respect to, the Company’s use of, or revenues derived from, technologies developed independently of Fraunhofer. On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) to create a new research and development plan for the development of a recombinant Yellow Fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. By its execution of the Amended Agreement, iBio again engaged Fraunhofer to act as the Company’s subcontractor for performance of research and development services for the new research and development plan covered by the Amended Agreement and to have Fraunhofer bill Fiocruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement with the proceeds of such billings and only the proceeds paid to Fraunhofer for its services so the Company’s expense is equal to its revenue and no profit would be recognized for these activities under the Amended Agreement. For the year ended June 30, 2.1 in research and development services were performed by Fraunhofer for the Company pursuant to the amended CLA. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio was at least 3.0 See Note 8 - Significant Vendors for additional information. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company’s requests for proposals for such 20,000 30,627 25,000 150,000 On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (“MUSC”) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $ 78,000 December 31, 2015 161,754 Lease – Bryan, Texas As discussed above, iBio CDMO is leasing its facility in Bryan, Texas from the Second Eastern Affiliate under the Sublease. See Note 10 for more details of the Sublease. The base rent is subject to increase annually in accordance with increases in the CPI. The Company incurred rent expense of $ 15,370 Lawsuits On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. The Court bifurcated the action to first resolve the threshold question in the case–the scope of iBio’s ownership of the technology developed or held by Fraunhofer–before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties’ written submissions and oral argument, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and was entitled to receive a technology transfer from Fraunhofer. Fraunhofer’s motion to dismiss iBio’s contract claims was denied by the Court on February 24, 2017. The Court at that time also granted, over Fraunhofer’s opposition, iBio’s motion to supplement and amend the Complaint to add additional state law claims against Fraunhofer. Fraunhofer filed an answer and counterclaims in March 2017, but in May 2017, Fraunhofer obtained new counsel, and with iBio’s agreement (as a matter of procedure), filed an amended answer and amended counterclaims in July 2017. The Company replied to those counterclaims on August 9, 2017 and included certain counter-counterclaims, which Fraunhofer moved to dismiss on August 30, 2017. The parties have continued to proceed with written discovery. On December 4, 2015, a putative derivative action captioned Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant

Segment Reporting

Segment Reporting	12 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	17. Segment Reporting In accordance with FASB ASC 280, “ Segment Reporting Year Ended June 30, 2017 (in thousands) iBio, Inc. iBio CDMO Eliminations Total Revenues - external customers $ 271 $ 123 $ - $ 394 Revenues - intersegment 972 1,280 (2,252) - Research and development 3,657 1,763 (1,303) 4,117 General and administrative 5,245 6,255 (949) 10,551 Operating loss (7,659) (6,615) - (14,274) Interest expense (1) (1,928) - (1,929) Interest and other income 43 21 - 64 Consolidated net loss (7,617) (8,522) - (16,139) Total assets 19,049 29,738 (12,777) 36,010 Fixed assets, net 8 25,581 - 25,589 Intangible assets, net 1,823 - - 1,823 Depreciation expense 3 1,323 - 1,326 Amortization of intangible assets 350 - - 350 Year Ended June 30, 2016 (in thousands) iBio, Inc. iBio CDMO * Eliminations Total Revenues - external customers $ 893 $ 55 $ - $ 948 Revenues - intersegment 158 324 (482) - Research and development 2,984 501 (329) 3,156 General and administrative 5,560 2,278 (153) 7,685 Operating loss (7,493) (2,400) - (9,893) Interest expense - (807) - (807) Interest and other income 33 10 - 43 Consolidated net loss (7,460) (3,197) - (10,657) Total assets 13,393 38,282 (75) 51,600 Fixed assets, net 8 25,566 - 25,574 Intangible assets, net 2,092 - - 2,092 Depreciation expense 4 573 - 577 Amortization of intangible assets 363 - - 363 * iBio CDMO commenced operations in December 2015.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on management's estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. The Company writes off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June 30, 2017 and 2016, the Company determined that an allowance for doubtful accounts was not needed.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In 2017 and 2016, grant income amounted to approximately $ 131,000 65,000
Inventory Work in Process, Policy [Policy Text Block]	Work in Process Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. Work in process totaled approximately $ 26,000 22,000
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with the FASB ASC 730-10, “ Research and Development
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years. Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 10).
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23
Derivatives, Policy [Policy Text Block]	Derivative Instruments The Company does not use derivative instruments in its ordinary course of business. In connection with the issuances of debt and/or equity instruments, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities rather than as equity. In addition, the debt and/or equity instrument may contain embedded derivative instruments, such as conversion options or anti-dilution features, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company accounts for derivative liability instruments under the provisions of FASB ASC 815, “ Derivatives and Hedging There are no options or warrants of the Company presently outstanding that require accounting as a derivative liability.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company accounts for foreign currency translation pursuant to FASB ASC 830, “ Foreign Currency Matters.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based Compensation The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates. The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at the date of grant or modification, and the vesting schedule. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June 30, 2017 and 2016. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2017 and 2016.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Cash The Company maintains principally all cash balances in one financial institution which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2017 and 2016, amounts in excess of insured limits were approximately $ 7,623,000 22,502,000

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands): June 30, June 30, Facility under capital lease $ 20,000 $ 20,000 Equipment under capital lease 6,000 6,000 Facility improvements 332 42 Medical equipment 905 - Office equipment and software 256 137 27,493 26,179 Accumulated depreciation – assets under capital lease (1,805) (571) Accumulated depreciation – other (99) (34) (1,904) (605) Net fixed assets $ 25,589 $ 25,574

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): June 30, June 30, Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,346 2,265 5,446 5,365 Intellectual property – accumulated amortization (2,088) (1,932) Patents – accumulated amortization (1,535) (1,341) (3,623) (3,273) Net intangible assets $ 1,823 $ 2,092
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands): For the Year Ending 2018 $ 335 2019 305 2020 273 2021 252 2022 238 Thereafter 420 Total $ 1,823

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following (in thousands): June 30, June 30, Rent and real estate taxes – related party (see Note 14) $ 330 $ 300 Interest – related party (see Note 14) 320 323 Professional fees 56 15 Salaries and benefits 111 55 Research and development - 122 Facility expenses - 53 Other accrued expenses 107 52 Total accrued expenses $ 924 $ 920

Capital Lease Obligation (Table

Capital Lease Obligation (Tables)	12 Months Ended
	Jun. 30, 2017
Table Text Block Supplement [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Future minimum payments under the capitalized lease obligations are due as follows: Year Ending: Principal Interest Total 2018 $ 183,110 $ 1,916,890 $ 2,100,000 2019 197,443 1,902,557 2,100,000 2020 212,898 1,887,102 2,100,000 2021 229,562 1,870,438 2,100,000 2022 247,531 1,852,469 2,100,000 Thereafter 24,194,146 34,080,854 58,275,000 Total minimum lease payments 25,264,690 $ 43,510,310 $ 68,775,000 Less: current portion (183,110) Long-term portion of minimum lease obligations $ 25,081,580

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2017
Stockholders Equity Note [Abstract]
Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes all warrant activity for 2017 and 2016: Warrants Weighted- Outstanding as of July 1, 2016 6,633,324 $ 1.63 Exercised (1,904,000) 0.53 Expired (4,729,324) 2.08 Outstanding as of June 30, 2016 - $ - Exercised - - Expired - - Outstanding as of June 30, 2017 - $ -

Earnings (Loss) Per Common Sh31

Earnings (Loss) Per Common Share (Tables)	12 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts): Years ended 2017 2016 Basic and diluted numerator: Net loss attributable to iBio, Inc. stockholders $ (14,532) $ (9,764) Preferred stock dividends (90) — Net loss available to iBio, Inc. stockholders $ (14,622) $ (9,764) Basic and diluted denominator: Weighted-average common shares outstanding 89,112 80,973 Per share amount $ (0.16) $ (0.12)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands): Year Ended 2017 2016 Research and development $ 26 $ 20 General and administrative 984 1,245 Totals $ 1,010 $ 1,265
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes all stock option activity during the years ended June 30, 2017 and 2016: Stock Weighted- Weighted- Aggregate Outstanding as of July 1, 2015 9,523,334 $ 1.22 6.6 $ 1,848 Granted 2,750,000 $ 1.64 Forfeited/expired - $ - Outstanding as of June 30, 2016 12,273,334 $ 1.31 6.4 $ 993 Granted 1,585,000 $ 0.40 Forfeited/expired (310,000) $ 1.11 Outstanding as of June 30, 2017 13,548,334 $ 1.21 5.9 $ 138 As of June 30, 2017 vested and expected to vest 13,486,342 $ 1.21 5.8 $ 138 Exercisable as of June 30, 2017 9,440,027 $ 1.30 4.7 $ 138
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: 2017 2016 Risk-free interest rate 2.05 2.46 1.83 2.13 Dividend yield 0 0 Volatility 103.10 104.38 109.49 112.17 Expected term (in years) 9 9

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Comprehensive Income (Loss) [Table Text Block]	The components of net loss consist of the following (in thousands): For the Years Ended 2017 2016 United States $ (16,122) $ (10,635) Brazil (17) (22) Total $ (16,139) $ (10,657)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision (benefit) for income taxes consist of the following (in thousands): For the Years Ended 2017 2016 Current – Federal, state and foreign $ - $ - Deferred – Federal (5,178) (260) Deferred – State (866) (9) Deferred – Foreign (4) (1) Total (6,048) (270) Change in valuation allowance 6,048 270 Income tax expense $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of June 30, 2017 2016 Deferred tax assets (liabilities): Net operating loss $ 17,827 $ 17,172 Share-based compensation 3,072 726 Research and development tax credits 1,285 1,097 Suspended losses in iBio CDMO 2,762 255 Basis in iBio CDMO 538 145 Intangible assets (267) (219) Vacation accrual and other 24 17 Valuation allowance (25,241) (19,193) Total $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of the statutory tax rate to the effective tax rate is as follows: Years Ended 2017 2016 Statutory federal income tax rate 34 % 34 % State (net of federal benefit) 6 % 6 % Research and development tax credit 1 % 1 % Permanent differences (5) % (7) % Reclassification of incentive stock options to non-qualifying 13 % - % Expiration of stock options and warrants - % (31) % Change in valuation allowance (49) % (3) % Effective income tax rate - % - %

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended June 30, 2017 (in thousands) iBio, Inc. iBio CDMO Eliminations Total Revenues - external customers $ 271 $ 123 $ - $ 394 Revenues - intersegment 972 1,280 (2,252) - Research and development 3,657 1,763 (1,303) 4,117 General and administrative 5,245 6,255 (949) 10,551 Operating loss (7,659) (6,615) - (14,274) Interest expense (1) (1,928) - (1,929) Interest and other income 43 21 - 64 Consolidated net loss (7,617) (8,522) - (16,139) Total assets 19,049 29,738 (12,777) 36,010 Fixed assets, net 8 25,581 - 25,589 Intangible assets, net 1,823 - - 1,823 Depreciation expense 3 1,323 - 1,326 Amortization of intangible assets 350 - - 350 Year Ended June 30, 2016 (in thousands) iBio, Inc. iBio CDMO * Eliminations Total Revenues - external customers $ 893 $ 55 $ - $ 948 Revenues - intersegment 158 324 (482) - Research and development 2,984 501 (329) 3,156 General and administrative 5,560 2,278 (153) 7,685 Operating loss (7,493) (2,400) - (9,893) Interest expense - (807) - (807) Interest and other income 33 10 - 43 Consolidated net loss (7,460) (3,197) - (10,657) Total assets 13,393 38,282 (75) 51,600 Fixed assets, net 8 25,566 - 25,574 Intangible assets, net 2,092 - - 2,092 Depreciation expense 4 573 - 577 Amortization of intangible assets 363 - - 363 * iBio CDMO commenced operations in December 2015.

Nature of Business (Details Tex

Nature of Business (Details Textual) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2017ft²	Feb. 23, 2017$ / shares	Jan. 13, 2016USD ($)	Dec. 31, 2015
BRAZIL
Nature of Business [Line Items]
Equity Method Investment, Ownership Percentage	99.00%
Second Eastern Affilate [Member]
Nature of Business [Line Items]
Area of Land | ft²	139,000
iBio CMO LLC [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		99.99%
Equity Method Investment, Ownership Percentage		0.01%
iBio CMO LLC [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Lease Term	34 years
iBio CMO [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent				100.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			70.00%
Equity Method Investment, Ownership Percentage		99.99%
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001
iBio CMO [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Amount Represented by Preferred Stock | $			$ 15
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			30.00%

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($)	Apr. 13, 2016	Jan. 13, 2016	May 15, 2015	Jul. 24, 2017	Jan. 25, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Nov. 20, 2014
Basis of Presentation [Line Items]
Accumulated deficit						$ (72,123,000)	$ (57,591,000)
Net Cash Used in Operating Activities						$ (13,163,000)	(8,072,000)
Stock Issued During Period, Shares, New Issues	6,500,000
Stock Issued During Period, Value, New Issues	$ 4,043,000			$ 1,000,000			$ 6,220,000
Common Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001
Class Of Warrants Or Rights Exercised						0	1,904,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0	$ 1.63
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total						$ (16,139,000)	$ (10,657,000)
Common Stock, Shares, Issued				1,200,000		89,118,510	89,109,410
Registration Payment Arrangement, Maximum Potential Consideration									$ 100,000,000
Eastern Affiliate [Member]
Basis of Presentation [Line Items]
Noncontrolling Interest, Description						Prior to the issuance of the shares of common stock pursuant to the purchase agreements with Eastern, Eastern beneficially owned approximately 30% of the Companys common stock, as reported in the Companys Annual Report on Form 10-K for the fiscal year ended June 30, 2015, filed with the SEC on October 13, 2015, calculated in accordance with the SECs beneficial ownership rules. As of the closing of the purchase agreements with Eastern and the simultaneous exercise by Eastern of its warrants to purchase iBio common stock, Eastern beneficially owned approximately 38% of the Companys outstanding shares of common stock. As of the filing date of this report, Eastern owns approximately 36.4% of the Companys outstanding common stock. See Note 11 in the consolidated financial statements
Aspire Capital Fund Llc [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			200,000
Stock Issued During Period, Value, New Issues			$ 500,000
Aspire Capital Fund Llc [Member] | Maximum [Member]
Basis of Presentation [Line Items]
Sale of Stock, Consideration Received on Transaction			$ 15,000,000
iBio CMO [Member] | Eastern [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues					3,500,000
Stock Issued During Period, Shares, Acquisitions		10,000,000
Common Stock, Par or Stated Value Per Share		$ 0.622
Class Of Warrants Or Rights Exercised					1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.53
Lincoln Park Capital Fund, LLC [Member]
Basis of Presentation [Line Items]
Aggregate Common Stock Purchased				$ 16,000,000
Stock Issued During Period, Shares, New Issues				2,500,000
Stock Issued During Period, Value, New Issues				$ 1,000,000
Common Stock, Shares, Issued				1,200,000
iBio CDMO [Member] | Eastern Affiliate [Member]
Basis of Presentation [Line Items]
Related Party Transaction, Description of Transaction						The Eastern Affiliate contributed $15 million in cash for a 30% interest in the Companys subsidiary iBio CDMO LLC (iBio CDMO). The Company retained a 70% interest in iBio CDMO and contributed a royalty bearing license which grants iBio CDMO a non-exclusive license to use the Companys proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Companys iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns 99.99% of iBio CDMO.
iBio CDMO [Member] | Eastern [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, Acquisitions						10,000,000
Proceeds From Capitalization Received						$ 15,000,000
Stock Issued During Period, Value, Acquisitions						$ 7,200,000

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Revenue from Grants	$ 131,000	$ 65,000
Work in process	26,000	22,000
Cash, FDIC Insured Amount	$ 7,623,000	$ 22,502,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	16 years
Property, Plant and Equipment, Estimated Useful Lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	23 years
Property, Plant and Equipment, Estimated Useful Lives	15 years
Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	10 years

Fixed Assets (Details)

Fixed Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment, Gross	$ 27,493	$ 26,179
Accumulated depreciation - assets under capital lease	(1,805)	(571)
Accumulated depreciation - other	(99)	(34)
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(1,904)	(605)
Net fixed assets	25,589	25,574
Facility Under Capital Lease [Member]
Property, Plant and Equipment, Gross	20,000	20,000
Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Gross	6,000	6,000
Facility Improvements [Member]
Property, Plant and Equipment, Gross	332	42
Medical equipment [Member]
Property, Plant and Equipment, Gross	905	0
Office Equipment [Member]
Property, Plant and Equipment, Gross	$ 256	$ 137

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Depreciation, Total	$ 1,326,000	$ 577,000
Capital Leased Assets [Member]
Depreciation, Total	$ 1,235,000	$ 571,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	$ 5,446	$ 5,365
Finite-Lived Intangible Assets, Accumulated Amortization	(3,623)	(3,273)
Net intangible assets	1,823	2,092
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	3,100	3,100
Finite-Lived Intangible Assets, Accumulated Amortization	(2,088)	(1,932)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	2,346	2,265
Finite-Lived Intangible Assets, Accumulated Amortization	$ (1,535)	$ (1,341)

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
2,018	$ 335
2,019	305
2,020	273
2,021	252
2,022	238
Thereafter	420
Total	$ 1,823	$ 2,092

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 350,000	$ 363,000
Gain (Loss) on Disposition of Intangible Assets	$ 0	33,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years 6 months
Gain (Loss) on Disposition of Intangible Assets	$ 0	$ (33,000)
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years 3 months 18 days

Significant Vendors (Details Te

Significant Vendors (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Significant Vendor [Line Items]
Accounts Payable, Current	$ 749,000	$ 1,177,000
Accrued Liabilities, Current	924,000	920,000
Research and Development Expense	4,117,000	3,156,000
Revenue, Net, Total	394,000	948,000
Amended Agreement [Member]
Significant Vendor [Line Items]
Research and Development Expense			$ 2,100,000
Revenue, Net, Total	137,000	758,000
Fraunhofer [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	75,000	341,000
Accrued Liabilities, Current	0	122,000
Novici [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	87,000	200,000
Research and Development Expense	$ 957,000	$ 1,036,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Total accrued expenses	$ 924	$ 920
Rent And Real Estate Tax Expense [Member]
Total accrued expenses	330	300
Interest Expense [Member]
Total accrued expenses	320	323
Professional fees [Member]
Total accrued expenses	56	15
Research and Development Expense [Member]
Total accrued expenses	0	122
Salaries and benefits [Member]
Total accrued expenses	111	55
Facility Expenses [Member]
Total accrued expenses	0	53
Other accrued expenses [Member]
Total accrued expenses	$ 107	$ 52

Capital Lease Obligation (Detai

Capital Lease Obligation (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
2,018	$ 2,100,000
2,019	2,100,000
2,020	2,100,000
2,021	2,100,000
2,022	2,100,000
Thereafter	58,275,000
Total minimum lease payments	68,775,000
Less: current portion	(183,000)	$ (170,000)
Long-term portion of minimum lease obligations	25,082,000	$ 25,265,000
Principal [Member]
2,018	183,110
2,019	197,443
2,020	212,898
2,021	229,562
2,022	247,531
Thereafter	24,194,146
Total minimum lease payments	25,264,690
Less: current portion	(183,110)
Long-term portion of minimum lease obligations	25,081,580
Interest [Member]
2,018	1,916,890
2,019	1,902,557
2,020	1,887,102
2,021	1,870,438
2,022	1,852,469
Thereafter	34,080,854
Total minimum lease payments	$ 43,510,310

Capital Lease Obligation (Det46

Capital Lease Obligation (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Capital Leases, Income Statement, Interest Expense	$ 1,928,000	$ 807,000
Sub Lease Expiration Period	34 years
Operating Leases, Rent Expense	$ 2,100,000
Capital Lease Obligation Description	the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMOs applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $107,000 and $27,000 in 2017 and 2016, respectively.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Class of Warrant or Right [Line Items]
Warrants, Outstanding	0	6,633,324
Warrants, Exercised	0	(1,904,000)
Warrants, Expired	0	(4,729,324)
Warrants, Outstanding		0
Weighted-average Exercise Price, Outstanding	$ 0	$ 1.63
Weighted-average Exercise Price, Exercised	0	0.53
Weighted-average Exercise Price, Expired	$ 0	2.08
Weighted-average Exercise Price, Outstanding		$ 0

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Apr. 13, 2016	Apr. 07, 2016	Jan. 13, 2016	May 15, 2015	Jul. 24, 2017	Feb. 23, 2017	Jan. 25, 2016	Apr. 28, 2015	Sep. 19, 2014	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Jun. 30, 2015	Aug. 25, 2014
Stockholders' Equity [Line Items]
Preferred Stock, Shares Authorized						1				1,000,000	1,000,000
Common Stock, Shares Authorized										175,000,000	175,000,000
Common Stock, Shares, Issued					1,200,000					89,118,510	89,109,410
Common Stock, Shares, Outstanding										89,118,510	89,109,410	89,118,510
Proceeds from Issuance of Common Stock										$ 0	$ 6,220,000
Proceeds from Warrant Exercises										0	1,009,000
Stock Issued During Period, Shares, New Issues	6,500,000
Stock Issued During Period, Value, New Issues	$ 4,043,000				$ 1,000,000						$ 6,220,000
Percentage Of Commitment Fee On Total Proceeds					3.00%
Share Price					$ 0.40
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0		$ 1.63
Registration Common Stock										$ 15,000,000
Common Stock, Par or Stated Value Per Share										$ 0.001	$ 0.001
Class Of Warrants Or Rights Exercised										0	1,904,000
Stockholders' Equity, Other Shares											9,100
Stockholders [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, Other		6,500,000
Eastern Share Purchase Agreements [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										120,000
Proceeds from Issuance of Common Stock										$ 64,000
Proceeds from Warrant Exercises							$ 945,000
Stock Issued During Period, Value, New Issues							$ 2,177,000
Stock Issued During Period, Shares, Other			6,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.53
Stock Issued During Period, Shares, Acquisitions			3,500,000
Common Stock, Par or Stated Value Per Share			$ 0.622
Class Of Warrants Or Rights Exercised							1,784,000
Maximum Common Stock Percentage			38.00%
Lincoln Park Purchase Agreement [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased					$ 16,000,000
Stock Issued During Period, Shares, New Issues					2,500,000
Stock Issued During Period, Shares, Other					100,000
Share Price					$ 0.25
Additional Aggregate Common Stock Purchased					$ 15,000,000
Aspire Capital Fund, LLC 2014 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										15,000,000
Sale of Stock, Price Per Share									$ 0.44	$ 0.44
Aggregate Common Stock Purchased				$ 15,000,000										$ 10,000,000
Proceeds from Issuance of Common Stock								$ 10,000,000		$ 10
Proceeds from Warrant Exercises										$ 8,768,806
Floor Price Of Common Stock										$ 0.20
Stock Issued During Period, Shares, New Issues									1,136,354	681,818
Stock Issued During Period, Value, New Issues									$ 500,000	$ 10,000,000
Percentage Of Commitment Fee On Total Proceeds										3.00%
Payments of Stock Issuance Costs										$ 300,000
Sale of Stock, Number of Shares Issued in Transaction										0.44
Percentage Of Aggregate Shares Of Company										30.00%
Percentage Of Closing Price Of Common Stock										80.00%
Percentage Of Volume Weighted Average Price										97.00%
Stock Issued During Period, Shares, Other										150,000
Share Price										$ 0.44
Aspire Capital Fund, LLC 2014 [Member] | November 2013 Private Placement Offering [Member]
Stockholders' Equity [Line Items]
Proceeds from Issuance of Common Stock										$ 500,000
Aspire Capital Fund, LLC 2014 [Member] | Registration Rights Agreement [Member]
Stockholders' Equity [Line Items]
Sale of Stock, Price Per Share										$ 0.44
Aspire Capital Fund, LLC 2015 [Member]
Stockholders' Equity [Line Items]
Commitment Shares Issued During Period				450,000
Maximum Amount Available For Purchase Of Shares										$ 15,000,000
Aspire Capital Fund, LLC 2015 [Member] | Aspirre Purchase Agreement 2015 [Member]
Stockholders' Equity [Line Items]
Percentage Of Common Stock Outstanding										19.99%
Commitment Shares Issued During Period										450,000
Stock Issued During Period, Shares, Other										15,343,406
Aspire Capital Fund Llc [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, New Issues				200,000
Stock Issued During Period, Value, New Issues				$ 500,000
Additional Purchase Of Shares				2,000,000
Preferred Tracking Stock [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Value, New Issues						$ 13,000,000
Preferred Stock, Dividend Rate, Percentage										2.00%
Dividends Payable										$ 90,000
Convertible Preferred Stock, Shares Issued upon Conversion						29,990,000
Preferred Stock, Par or Stated Value Per Share						$ 0.001
Noncontrolling Interest, Ownership Percentage by Parent						99.99%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						0.01%
Maximum [Member] | Lincoln Park Purchase Agreement [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased					$ 1,000,000

Earnings (Loss) Per Common Sh49

Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Basic and diluted numerator:
Net loss attributable to iBio, Inc. stockholders	$ (14,532)	$ (9,764)
Preferred stock dividends	(90)	0
Net loss available to iBio, Inc. stockholders	$ (14,622)	$ (9,764)
Basic and diluted denominator:
Weighted-average common shares outstanding	89,112	80,973
Per share amount	$ 0.16	$ 0.12

Earnings (Loss) Per Common Sh50

Earnings (Loss) Per Common Share (Details Textual) - shares shares in Millions	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Warrant [Member]
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants		12.3
Employee Stock Option [Member]
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants	13.5

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 1,010	$ 1,265
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	26	20
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 984	$ 1,245

Share-Based Compensation (Det52

Share-Based Compensation (Details 1) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Outstanding at beginning of the period	12,273,334	9,523,334
Stock Options, Granted	1,585,000	2,750,000
Stock Options, Forfeited/expired	(310,000)	0
Stock Options, Outstanding at end of the period	13,548,334	12,273,334	9,523,334
Stock Options, Vested and, as of June 30, 2017, expected to vest	13,486,342
Stock Options, Exercisable as of June 30, 2017	9,440,027
Weighted-average Exercise Price, Outstanding at beginning of the period	$ 1.31	$ 1.22
Weighted-average Exercise Price, Granted	0.40	1.64
Weighted-average Exercise Price, Forfeited/expired	1.11	0
Weighted-average Exercise Price, Outstanding at end of the period	1.21	$ 1.31	$ 1.22
Weighted-average Exercise Price, Vested and, as of June 30, 2017, expected to vest	1.21
Weighted-average Exercise Price, Exercisable as of June 30, 2017	$ 1.30
Weighted-average Remaining Contractual Term (in years), Outstanding	5 years 10 months 24 days	6 years 4 months 24 days	6 years 7 months 6 days
Weighted-average Remaining Contractual Term (in years), Vested and, as of June 30, 2017, expected to vest	5 years 9 months 18 days
Weighted-average Remaining Contractual Term (in years), Exercisable as of June 30, 2017	4 years 8 months 12 days
Aggregate Intrinsic Value ,Outstanding	$ 138	$ 993	$ 1,848
Aggregate Intrinsic Value, Vested and, as of June 30, 2017, expected to vest	138
Aggregate Intrinsic Value, Exercisable as of June 30, 2017	$ 138

Share-Based Compensation (Det53

Share-Based Compensation (Details 2)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Dividend yield	0.00%	0.00%
Volatility, Minimum	103.10%	109.49%
Volatility, Maximum	104.38%	112.17%
Expected term (in years)	9 years	9 years
Minimum [Member]
Risk-free interest rate	2.05%	1.83%
Maximum [Member]
Risk-free interest rate	2.46%	2.13%

Share-Based Compensation (Det54

Share-Based Compensation (Details Textual) - USD ($)	Mar. 01, 2017	Sep. 04, 2015	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Aug. 12, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 0.36	$ 0.62
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars)			$ 1.1	$ 1.1
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition				1 year 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,585,000	2,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 0.40	$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period, Description				Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 1,239,000	$ 800,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)						10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 0.40
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				10 years
Board Of Directors And Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,435,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.40
Board of Directors, Officers and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			10 years
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	150,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.40
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	Apr. 13, 2016	Jul. 24, 2017	Mar. 31, 2017	Feb. 23, 2017	Dec. 31, 2015	Nov. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current							$ 87,000	$ 200,000
Research and Development Expense							4,117,000	$ 3,156,000
Operating Leases, Rent Expense							$ 2,100,000
Stock Issued During Period, Shares, New Issues	6,500,000
Common Stock, Par or Stated Value Per Share							$ 0.001	$ 0.001
Class Of Warrants Or Rights Exercised							0	1,904,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0	$ 1.63
Stock Issued During Period, Value, New Issues	$ 4,043,000	$ 1,000,000						$ 6,220,000
Preferred Tracking Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, New Issues				$ 13,000,000
Preferred Stock, Par or Stated Value Per Share				$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion				29,990,000
iBio CMO LLC [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage				0.01%
Noncontrolling Interest, Ownership Percentage by Parent				99.99%
Eastern Two Share Purchase Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues							10,000,000
Common Stock, Par or Stated Value Per Share							$ 0.622
Class Of Warrants Or Rights Exercised							1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.53
Stock Issued During Period, Value, New Issues							$ 6,220,000
Eastern Capital Limited and its Affiliates [Member] | Retained Interest [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners							70.00%
Eastern Capital Limited and its Affiliates [Member] | iBio CMO LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Due from (to) Related Party, Total							$ 15,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners							30.00%
Second Eastern Affilate [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current							$ 650,000	1,784,000
Research and Development Expense								565,000
Interest Expense, Debt							1,928,000	807,000
Other General And Administrative Expense							$ 775,000	945,520
Stockholders [Member] | Standstill Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues							6,500,000
Director [Member] | Standstill Agreements [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage							38.00%
Novici Biotech LLC [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current							$ 87,000	200,000
Research and Development Expense							957,000	1,036,000
Related Party [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense			$ 0.53		$ 2,500	$ 2,200	$ 50,000	$ 28,500

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Net Loss For Income Tax [Line Items]
Net (Loss)	$ (14,532)	$ (9,764)
United States
Net Loss For Income Tax [Line Items]
Net (Loss)	(16,122)	(10,635)
Brazil
Net Loss For Income Tax [Line Items]
Net (Loss)	$ (17)	$ (22)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Provision For Income Taxes [Line Items]
Current - Federal, state and foreign	$ 0	$ 0
Deferred - Federal	(5,178)	(260)
Deferred - State	(866)	(9)
Deferred - Foreign	(4)	(1)
Total	(6,048)	(270)
Change in valuation allowance	6,048	270
Income tax expense	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 30, 2016
Deferred tax assets (liabilities):
Net operating loss	$ 17,827	$ 17,172
Share-based compensation	3,072	726
Research and development tax credits	1,285	1,097
Suspended losses in iBio CMO	2,762	255
Basis in iBio CMO	538	145
Intangible assets	(267)	(219)
Vacation accrual and other	24	17
Valuation allowance	(25,241)	(19,193)
Total	$ 0	$ 0

Income Taxes (Details 3)

Income Taxes (Details 3)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Statutory federal income tax rate	34.00%	34.00%
State (net of federal benefit)	6.00%	6.00%
Research and development tax credit	1.00%	1.00%
Permanent differences	(5.00%)	(7.00%)
Reclassification of incentive stock options to non-qualifying	13.00%	0.00%
Expiration of stock options and warrants	0.00%	(31.00%)
Change in valuation allowance	(49.00%)	(3.00%)
Effective income tax rate	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2008
Income Taxes [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ (50,100,000)		$ (5,500,000)
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	(12,900,000)
Deferred Tax Assets, Tax Credit Carryforwards, Research	1,285,000	$ 1,097,000
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	$ (119,000)

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jan. 14, 2017	Dec. 31, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Dec. 30, 2013	Apr. 30, 2013
Commitments and Contingencies [Line Items]
Research and Development Expense, Total			$ 4,117,000	$ 3,156,000
Royalty Guarantees, Commitments, Amount			$ 200,000
Long Term Purchase Commitment Expire Date			Dec. 31, 2015
Operating Leases, Rent Expense			$ 2,100,000
Commitments [Member]
Commitments and Contingencies [Line Items]
Research Services Agreements Value Fulfilling Commitment		$ 3,000,000
License Costs	$ 30,627
Initial license fee	20,000
Contractual Obligation, Due in Next Twelve Months						$ 78,000
Contractual Obligation, Due in Second Year						$ 161,754
Settlement Agreement [Member]
Commitments and Contingencies [Line Items]
Prepaid Expense							$ 1,000,000
Amended Agreement [Member]
Commitments and Contingencies [Line Items]
Research and Development Expense, Total					$ 2,100,000
Second Eastern Affilate [Member]
Commitments and Contingencies [Line Items]
Research and Development Expense, Total				$ 565,000
Minimum [Member] | Commitments [Member]
Commitments and Contingencies [Line Items]
License Costs	25,000
Maximum [Member] | Commitments [Member]
Commitments and Contingencies [Line Items]
License Costs	$ 150,000
Fraunhofer [Member]
Commitments and Contingencies [Line Items]
Royalty Guarantees, Commitments, Amount		$ 3,000,000	$ 4,000,000
Other Commitments, Description			the 2013 Settlement Agreement provided that, for a period of up to 15 years, the Company would pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing those technologies to third parties
iBio CDMO [Member] | Second Eastern Affilate [Member]
Commitments and Contingencies [Line Items]
Operating Leases, Rent Expense			$ 15,370

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Revenues - external customers	$ 394	$ 948
Revenues - intersegment	0	0
Research and development	4,117	3,156
General and administrative	10,551	7,685
Operating loss	(14,274)	(9,893)
Interest expense	(1,929)	(807)
Interest and other income	64	43
Consolidated net loss	(16,139)	(10,657)
Total assets	36,010	51,600
Fixed assets, net	25,589	25,574
Intangible assets, net	1,823	2,092
Depreciation expense	1,326	577
Amortization of intangible assets	350	363
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	0	0
Revenues - intersegment	(2,252)	(482)
Research and development	(1,303)	(329)
General and administrative	(949)	(153)
Operating loss	0	0
Interest expense	0	0
Interest and other income	0	0
Consolidated net loss	0	0
Total assets	(12,777)	(75)
Fixed assets, net	0	0
Intangible assets, net	0	0
Depreciation expense	0	0
Amortization of intangible assets	0	0
iBio CDMO [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	123	55	[1]
Revenues - intersegment	1,280	324	[1]
Research and development	1,763	501	[1]
General and administrative	6,255	2,278	[1]
Operating loss	(6,615)	(2,400)	[1]
Interest expense	(1,928)	(807)	[1]
Interest and other income	21	10	[1]
Consolidated net loss	(8,522)	(3,197)	[1]
Total assets	29,738	38,282	[1]
Fixed assets, net	25,581	25,566	[1]
Intangible assets, net	0	0	[1]
Depreciation expense	1,323	573	[1]
Amortization of intangible assets	0	0	[1]
iBio, Inc [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	271	893
Revenues - intersegment	972	158
Research and development	3,657	2,984
General and administrative	5,245	5,560
Operating loss	(7,659)	(7,493)
Interest expense	(1)	0
Interest and other income	43	33
Consolidated net loss	(7,617)	(7,460)
Total assets	19,049	13,393
Fixed assets, net	8	8
Intangible assets, net	1,823	2,092
Depreciation expense	3	4
Amortization of intangible assets	$ 350	$ 363
[1]	iBio CDMO commenced operations in December 2015.